Pieris Pharmaceuticals, Inc. (PIRS)

Market Cap	22.46M
Revenue (ttm)	40.93M
Net Income (ttm)	-16.25M
Shares Out	1.32M
EPS (ttm)	-11.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,965
Open	16.53
Previous Close	17.31
Day's Range	16.51 - 17.96
52-Week Range	6.20 - 41.76
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 8, 2024

About PIRS

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partners...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Stephen S. Yoder J.D.
• Employees: 50
• Stock Exchange: NASDAQ
• Ticker Symbol: PIRS

Financial Performance

In 2023, PIRS's revenue was $42.81 million, an increase of 65.28% compared to the previous year's $25.90 million. Losses were -$24.54 million, -26.25% less than in 2022.